Navigation Links
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Date:11/5/2012

PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients.  SAR236553/REGN727 is an investigational subcutaneously administered, fully-human antibody that is being evaluated for its impact on lowering low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The ODYSSEY OUTCOMES trial will enroll approximately 18,000 patients, who recently suffered an acute coronary syndrome (ACS), from 49 countries across six continents.  With the start of this study, eleven trials are now recruiting in the global SAR236553/REGN727 Phase 3 program.

"Despite widespread use of statin therapy, many patients at risk do not reach recommended targets for LDL.  Even among those who do reach targets, further LDL lowering may further reduce the risks of coronary heart disease (CHD) death, myocardial infarction (MI) and stroke," said Ph. Gabriel Steg M.D., Professor of Cardiology at the Hopital Bichat-Claude Bernard in Paris, France, and co-Chair of the ODYSSEY OUTCOMES Steering Committee.  "The ODYSSEY cardiovascular (CV) outcomes trial will test the efficacy and safety of SAR236553/REGN727 added to maximal doses of statins in reducing cardiovascular morbidity and mortality in patients with recent ACS, a population at high risk of CV events despite best contemporary therapy."

ODYSSEY OUTCOMES is a double-blind, randomized, placebo-controlled, multi-national study.  The primary objective of the study is to evaluate the effect of SAR236553/REGN727 on the incidence of cardiovascular events in patien
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Regeneron Announces June 2012 Investor Conference Presentations
8. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
9. Regeneron Announces September 2012 Investor Conference Presentations
10. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
11. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK and KISSING, Germany ... manufacturer and distributor of a single use and computer-assisted ... Nachum (Homi) Shamir , a worldwide recognized medical device ... Mr. Shamir is a highly respected ... most recent assignment he served as President and Chief ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , SAN FRANCISCO, Nov. 4 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular ... Senior Vice President Research & Development will present "VIA-3196, ... in the Abstract Oral Session on Novel Biological Mechanisms ...
... CVS Caremark (NYSE: CVS ) today announced ... SVP, Marketing for its pharmacy benefit management business. ... Jack Bruner, who is transitioning to the new role ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings twenty years ...
Cached Medicine Technology:VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4Company Appoints New SVP, Marketing for PBM Business 2
(Date:7/30/2014)... Victory Medical Center Craig Ranch , ... launch of a pediatric unit focused on: orthopedics, ear, ... working in the pediatrics departments are all specially trained ... Dr. Timothy Cole, Dr. Dale Ehmer, Dr. Barry Humeniuk, ... and Dr. Nicholas Peiffer lead the pediatrics team. Victory ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) into the ... Westchester County takes the best of everything. Leading physicians, ... structure and protocols, and a staff that is second ... Financial Officer to help run it. According to the ... possesses. In fact, in the WCBJ’s July 21st, 2014 ...
(Date:7/30/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- A simple ... as spina bifida, new research finds. The test ... B) in a pregnant women,s red blood cells. The findings ... scientists -- could help doctors predict the risk of serious ... vital to the proper development of a growing fetus. ...
(Date:7/30/2014)... Tallahassee, FL (PRWEB) July 30, 2014 ... engineering doctoral candidate Renee Gordon and biochemistry professor ... August to conduct research as Fulbright Scholars. The ... international education exchange program that awards grants to ... teach and conduct research abroad. Both Gordon and ...
(Date:7/30/2014)... As a leading outpatient surgery clinic ... boasts over 50 of the best physicians across fourteen ... Health Systems’ team are Dr. Benjamin Basseri and Dr. ... , Benjamin Basseri, MD, is a board-certified gastroenterologist. He ... followed by a fellowship in Gastroenterology at UCLA Medical ...
Breaking Medicine News(10 mins):Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3Health News:Blood Test Might Help Prevent Certain Birth Defects 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 3Health News:La Peer Welcomes Two New Gastroenterologists 2Health News:La Peer Welcomes Two New Gastroenterologists 3
... (Nasdaq: SIAL ) is pleased to announce ... Corporate Controller effective April 13, 2009. Kanan (age 46) ... President-Strategy & Corporate Development. He will report to ... brings two decades of financial experience in assignments of ...
... Reovirus seeks out and destroys tumor cells, researchers say ... harmless human virus can target and kill breast cancer ... reovirus might be effective against cancer stem cells, because ... destroys regular cancer cells," Dr. Patrick Lee, a cancer ...
... Tau has been promoted to the position of Service ... at Baron Center, Inc (BCI). Dr. Tau is ... & forensic psychology. Dr. Tau is an expert in ... and has been extensively used as a workplace violence ...
... at Johns Hopkins have begun to tease out what there ... that leads so many patients to report depression after they ... 10 in Critical Care Medicine , the Hopkins researchers ... hospitalization among very sick ICU patients, including a high level ...
... dopamine agonists appear to curb compulsive acting out, study ... class of Parkinson,s disease drugs called dopamine agonists can ... gambling or hypersexuality, says a new study. , ... taking therapeutic doses of dopamine agonists, such as pramipexole ...
... Sinai faculty suggests that a gene associated with onset ... cases. The research, led by Dr. Giulio Maria Pasinetti, ... Professor of Psychiatry and Geriatrics and Adult Development at ... in the scientific journal, Archives of Neurology . ...
Cached Medicine News:Health News:Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller 2Health News:Harmless Virus May Be Deadly to Breast Cancer 2Health News:Manny Tau, Psy.D. Promoted to Service Area Leader for the Problematic Behaviors Service Area at Baron Center, Inc 2Health News:In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression 2Health News:Parkinson's Drugs Can Trigger Unhealthy Behaviors 2Health News:Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimer's disease 2
Inquire...
Sealing Mat for 384-well, Square Well Plates Available Sterile...
96-well Silicone Expansion Mat, Bulk...
Microseal 'M' mats, seals 96-well plates, reusable, pkg of 10...
Medicine Products: